idiopath
pneumonia
syndrom
ip
sever
morbid
complic
hematopoiet
cell
transplant
hct
larg
lack
effect
treatment
syndrom
defin
abnorm
pulmonari
physiolog
multilobar
opac
chest
imag
attribut
lower
respiratori
tract
infect
lrti
organ
failur
mani
patholog
meet
ip
criteria
includ
organ
pneumonia
interstiti
pneumon
diffus
alveolar
damag
among
other
biolog
heterogen
within
broadli
defin
syndrom
may
diminish
abil
detect
effect
treatment
improv
understand
ip
pathobiolog
may
catalyz
develop
effect
prevent
therapeut
strategi
sever
proinflammatori
cytokineschemokin
elev
ip
biomark
may
use
distinguish
ip
subphenotyp
uniqu
biolog
featur
preliminari
examin
concept
test
hypothesi
immunoinflammatori
mediat
measur
blood
alveolar
compart
peopl
ip
differ
accord
presenc
absenc
diffus
alveolar
hemorrhag
dah
dah
variabl
present
manifest
ip
propos
distinct
biolog
retrospect
studi
adult
underw
clinic
bronchoscopi
diffus
abnorm
chest
imag
within
day
allogen
hct
fred
hutchinson
cancer
research
center
fhcrc
none
receiv
specif
tumor
necrosi
factor
tnf
inhibitor
prior
bronchoscopi
data
sampl
bank
prospect
subject
consent
fhcrc
protocol
approv
use
research
fhcrc
protocol
review
pertin
progress
note
microbiolog
report
patholog
report
bronchoscopi
report
radiograph
imag
identifi
ip
case
accord
american
thorac
societi
definit
defin
abnorm
respiratori
physiolog
oxygen
satur
puls
oximetri
arteri
blood
ga
breath
ambient
air
supplement
oxygen
defin
lrti
bronchoalveolar
lavag
fluid
balf
grow
amount
gramneg
rod
mycoplasma
spp
chlamydophila
spp
fungimold
legionella
nocardia
mycobacteria
colonyform
unit
per
ml
singl
pathogen
gramposit
coccu
cytomegaloviru
cmv
infect
requir
cultur
pcr
posit
also
classifi
lrti
posit
direct
fluoresc
antibodi
stain
pcr
copi
respiratori
virus
adenoviru
coronaviru
parainfluenza
influenza
ab
respiratori
syncyti
viru
human
metapneumoviru
herp
simplex
varicella
zoster
posit
stain
pneumocysti
jirovecii
balf
serum
galactomannan
ngl
dah
requir
document
increasingli
bloodi
return
serial
bronchoalveolar
lavag
report
bloodi
balf
follow
treatment
system
corticosteroid
clinic
diagnos
dah
accord
local
protocol
blood
sampl
drawn
weekli
interv
survey
cmv
process
cryopreserv
immedi
use
local
standard
oper
procedur
avail
select
blood
sampl
collect
prior
bronchoscopi
within
day
bronchoscopi
best
reflect
biolog
activ
time
bronchoscopi
balf
sampl
obtain
use
standard
clinic
techniqu
cryopresev
without
process
thaw
sampl
ice
batch
centrifug
min
remov
debri
batchanalyz
duplic
broad
array
immunoinflammatori
cytokin
chemokin
growth
factor
use
commerci
avail
multiplex
immunoassay
kit
per
manufactur
guidelin
meso
scale
rockvil
md
gener
standard
curv
use
serial
dilut
standard
sampl
matric
known
concentr
determin
analyt
concentr
use
meso
scale
discoveri
workbench
version
copyright
individu
analyt
concentr
sd
less
mean
signal
blank
control
replac
valu
pgml
analyt
n
analyt
signal
sd
mean
signal
blank
left
unchang
perform
twoway
analysi
varianc
base
intraclass
correl
coeffici
interleukin
il
drop
balf
plasma
addit
macrophagederiv
chemokin
mdc
thymu
activationregul
chemokin
tarc
drop
balf
drop
plasma
summar
concentr
replic
sampl
mean
use
twosampl
wilcoxon
ranksum
test
statist
comparison
statist
analysi
plan
perform
research
team
member
relev
expertis
vand
vuss
wurfel
comput
code
request
address
correspond
author
use
stataic
softwar
statacorp
lp
colleg
station
tx
data
analysi
defin
statist
signific
twosid
p
eleven
subject
met
criteria
dah
five
without
five
subject
evid
lrti
exclud
one
subject
congest
heart
failur
analys
sever
condit
regimen
use
clinic
provid
discret
mortal
high
group
tabl
cytokin
chemokin
level
highli
variabl
tabl
balf
concentr
higher
subject
ip
dah
nondah
ip
blood
biomark
differ
group
data
shown
biomark
elev
balf
subject
dah
mediat
recruit
activ
innat
adapt
immun
effector
cell
find
consist
higher
level
immun
system
activ
alveolar
compart
peopl
ip
dah
nondah
ip
dah
may
clinic
manifest
uniqu
lungloc
pathobiolog
would
recogn
measur
blood
biomark
alon
given
number
comparison
made
broad
examin
biomark
statist
signific
find
may
fals
posit
preclin
clinic
studi
contribut
importantli
current
understand
ip
reassuringli
result
similar
found
experiment
model
clinic
set
panoskaltsismortari
et
al
examin
lung
protein
extract
serum
balf
murin
ip
model
expos
cyclophosphamid
total
bodi
irradi
allogen
hct
natur
killer
nk
cell
deplet
spleen
cell
infus
tcell
sourc
studi
demonstr
timevari
elev
messeng
rna
express
protein
product
compart
rel
healthi
control
anoth
preclin
studi
express
earli
irradi
mice
receiv
allogen
bone
marrow
transplant
experiment
disrupt
either
receptor
lower
balf
monocyt
macrophag
latter
case
tcell
count
lessen
histopatholog
lung
injuri
clinic
studi
demonstr
level
elev
balf
collect
peopl
ip
rel
healthi
control
individu
chronic
noninfecti
lung
diseas
hct
one
observ
studi
balf
sampl
antagonist
therapi
demonstr
decreas
inflammatori
mediat
subset
subject
experienc
clinic
improv
studi
extend
find
suggest
ip
subtyp
may
differ
inflammatori
profil
therefor
differ
respons
immunomodulatori
therapi
recent
studi
appli
modern
molecular
diagnost
techniqu
balf
sampl
individu
previous
diagnos
ip
found
occult
virus
unknown
clinic
signific
post
hoc
analysi
examin
distribut
preval
occult
viru
known
human
pathogen
use
realtim
quantit
fluoresc
probe
pcr
assay
previous
describ
eight
studi
subject
posit
similarli
distribut
subject
without
ip
subject
ip
dah
subject
nondah
ip
balf
plasma
cytokin
level
differ
ip
case
ip
case
without
data
shown
although
possibl
current
ip
definit
misclassifi
infect
clearli
drive
find
studi
futur
research
must
consid
potenti
role
occult
viral
infect
defin
ip
subphenotyp
research
sever
potenti
limit
small
studi
lack
atrisk
control
may
underpow
detect
differ
lack
standard
method
correct
dilut
balf
may
introduc
error
impact
therapeut
corticosteroid
cryopreserv
unprocess
balf
variabl
time
sampl
collect
result
unknown
onset
nondah
ip
occur
later
ip
dah
often
engraft
studi
dah
may
surrog
import
biolog
differ
earli
lateronset
ip
altern
differ
found
may
relat
time
pass
instead
vari
biolog
confirmatori
prospect
valid
studi
need
ideal
collect
process
plasma
balf
simultan
analysi
protein
level
leukocyt
express
cellular
profil
may
help
elucid
import
biolog
differ
ip
subtyp
conclus
immun
system
particularli
activ
dah
phenotyp
ip
occur
within
day
allogen
hct
relev
small
studi
lie
potenti
influenc
futur
research
find
support
hypothesi
ip
includ
spectrum
patholog
may
differenti
respond
risk
factor
modif
therapi
heterogen
natur
current
ip
definit
may
allow
research
reveal
true
effect
immun
modul
therapi
futur
research
need
identifi
biolog
distinct
ip
subphenotyp
progress
toward
precis
medicin
improv
outcom
